Siplizumab
From Wikipedia, the free encyclopedia
Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.[1]
[edit] References
- ^ ClinicalTrials.gov
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
|
|
|
Unsorted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immune system ("-l(i[m])-") |
|
Human ("-limu-")
|
|
|
|
Mouse ("-limo-")
|
|
|
|
|
|
|
|
|
|
|
|
Chimeric + humanized
("-lixizu-")
|
|
|
|
| Interleukin ("-k(i[n])-") |
|
Human ("-kinu-")
|
|
|
|
Humanized ("-kizu-", "-kinzu-")
|
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
|
(what is this?) (verify)
